Characteristics of case and control subjects at time of ASCT and results of analysis according to FCM
| Variable . | Case subjects . | Control subjects . | P* . |
|---|---|---|---|
| Baseline characteristics at ASCT | |||
| No. of patients | 36 | 36 | |
| Age at ASCT, median (range), y | 55.0 (29-69) | 56.6 (35-67) | .50 |
| Sex, female/male | 7/29 | 7/29 | |
| Follow-up, median (range), y | 3.5 (0.2-18.1) | 8.2 (2.2-16.7) | < .001 |
| Cytotoxic treatment post-ASCT, yes/no | 0.38 | 0.50 | .393 |
| Read depth of NGS, median (range) | 8 606 (4 540-10 866) | 9 061 (7 027-10 016) | .350 |
| Admittance, median (range), d | 15.1 (11-31) | 15.5 (10-29) | .680 |
| Reg. neutrophil granulocytes, median (range), d | 11.2 (9-28) | 10.8 (9-15) | .576 |
| Reg. platelets, median (range), d | 17.4 (9-70) | 15.1 (9-36) | .367 |
| CD34+ cells, median (range), ×106/kg | 3.57 (0.4-29) | 5.32 (2-18) | .016 |
| FCM | |||
| CD34+CD38– fraction, median (range), % | 0.022 (0.004-0.14) | 0.015 (0.0001-0.06) | < .001 |
| CD34+CD38–CLEC12A+, % (CI 95%), yes/no | 3.1 (0.07-16.21) | 2.7 (0.07-14.52) | .933 |
| CD34+CD38–CD7+, % (CI 95%), yes/no | 37.5 (21.1-56.3) | 8.3 (1.7-22.4) | .004 |
| CD34+CD38–CD19+, % (CI 95%), yes/no | 0 | 0 | |
| CD34+CD38–CD123+, % (CI 95%), yes/no | 15.6 (5.2-32.7) | 8.3 (1.7-22.4) | .352 |
| Variable . | Case subjects . | Control subjects . | P* . |
|---|---|---|---|
| Baseline characteristics at ASCT | |||
| No. of patients | 36 | 36 | |
| Age at ASCT, median (range), y | 55.0 (29-69) | 56.6 (35-67) | .50 |
| Sex, female/male | 7/29 | 7/29 | |
| Follow-up, median (range), y | 3.5 (0.2-18.1) | 8.2 (2.2-16.7) | < .001 |
| Cytotoxic treatment post-ASCT, yes/no | 0.38 | 0.50 | .393 |
| Read depth of NGS, median (range) | 8 606 (4 540-10 866) | 9 061 (7 027-10 016) | .350 |
| Admittance, median (range), d | 15.1 (11-31) | 15.5 (10-29) | .680 |
| Reg. neutrophil granulocytes, median (range), d | 11.2 (9-28) | 10.8 (9-15) | .576 |
| Reg. platelets, median (range), d | 17.4 (9-70) | 15.1 (9-36) | .367 |
| CD34+ cells, median (range), ×106/kg | 3.57 (0.4-29) | 5.32 (2-18) | .016 |
| FCM | |||
| CD34+CD38– fraction, median (range), % | 0.022 (0.004-0.14) | 0.015 (0.0001-0.06) | < .001 |
| CD34+CD38–CLEC12A+, % (CI 95%), yes/no | 3.1 (0.07-16.21) | 2.7 (0.07-14.52) | .933 |
| CD34+CD38–CD7+, % (CI 95%), yes/no | 37.5 (21.1-56.3) | 8.3 (1.7-22.4) | .004 |
| CD34+CD38–CD19+, % (CI 95%), yes/no | 0 | 0 | |
| CD34+CD38–CD123+, % (CI 95%), yes/no | 15.6 (5.2-32.7) | 8.3 (1.7-22.4) | .352 |
Reg, regeneration.
P values for Wilcoxon-Mann-Whitney test and Pearson χ2 test.